文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

EASIX与m-EASIX预测儿童及青少年和年轻成人CD19-CAR T细胞治疗后细胞因子释放综合征和免疫效应细胞相关神经毒性综合征

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy.
PubMed 文献 · Blood Adv · 2025-01-01

该回顾性研究纳入76例在St. Jude儿童研究医院或约翰霍普金斯医院接受CD19-CAR T细胞治疗的复发/难治性B细胞急性淋巴细胞白血病儿童及青少年和年轻成人患者,于CAR T细胞输注前5天、输注当天及输注后3天计算EASIX和m-EASIX评分。47例发生细胞因子释放综合征(CRS),17例发生免疫效应细胞相关神经毒性综合征(ICANS);所有评估时间点,发生重度CRS和任何级别ICANS的患者EASIX中位评分更高,发生重度CRS和重度ICANS的患者m-EASIX中位评分更高。ROC曲线分析显示两评分均为CRS的强预测因子,任何级别和重度ICANS在+3天预测最佳,除预测任何级别ICANS外m-EASIX均优于EASIX。

要点

  • 在儿童及青少年和年轻成人中验证EASIX和m-EASIX对CAR T细胞相关CRS和ICANS的预测效用。
  • 47例发生CRS,17例发生ICANS;重度CRS和任何级别ICANS患者各时间点EASIX中位评分更高。
  • 除预测任何级别ICANS外,m-EASIX在各时间点预测CRS和ICANS均优于EASIX。

核心结论

  • 研究结果验证了EASIX和m-EASIX评分在儿童及青少年和年轻成人患者中预测CAR T细胞相关并发症的潜在效用。

研究设计与样本

  • 回顾性研究,纳入76例在St. Jude儿童研究医院或约翰霍普金斯医院接受CD19-CAR T细胞治疗的复发/难治性B细胞急性淋巴细胞白血病儿童及青少年和年轻成人患者。
  • 于CAR T细胞输注前5天、输注当天(第0天)及输注后3天计算EASIX和m-EASIX评分。

主要发现

  • 47例发生CRS,17例发生ICANS。
  • 所有评估时间点,发生重度CRS和任何级别ICANS的患者EASIX中位评分更高。
  • 所有评估时间点,发生重度CRS和重度ICANS的患者m-EASIX中位评分高于无/轻度CRS/ICANS患者。
  • ROC曲线分析显示两评分在所有时间点均为CRS(尤其是重度CRS)的强预测因子;任何级别和重度ICANS在+3天预测最佳。
  • 除预测任何级别ICANS外,m-EASIX在各时间点预测均优于EASIX。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are complications of CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy. The Endothelial Activation and Stress Index (EASIX) and modified EASIX (m-EASIX) scores have been retrospectively proven to be predictive of CRS and ICANS in adult CAR T-cell recipients. However, these scores have not been evaluated in pediatric cohorts. We retrospectively report on 76 pediatric and adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with CD19-CAR T cells at St. Jude Children's Research Hospital or Johns Hopkins Hospital. Data included patient, disease, and treatment characteristics. EASIX and m-EASIX scores were calculated at days -5 before, 0, and +3 after CAR T-cell infusion. CRS and ICANS occurred in 47 and 17 patients, respectively. At all evaluated time points, the median EASIX scores were higher for patients who developed severe CRS and any grade ICANS, and the median m-EASIX scores were higher in patients who developed severe CRS and severe ICANS than those with no/mild CRS/ICANS. Receiver operating characteristic curve analysis showed that both scores were strong predictors of CRS, especially severe CRS, at all time points. Any grade and severe ICANS were best predicted by both scores at day +3. m-EASIX uniformly outperformed EASIX, except for predicting any grade ICANS. Our results validate the potential utility of EASIX and m-EASIX scores for predicting CAR T-cell-related complications for pediatric and AYA patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zandaki D, Selukar S, Bi Y, et al. EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2025. PMID: 39325974. doi:10.1182/bloodadvances.2024014027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。